Business Context and Reporting Period
This Form 8-K Current Report was filed by Supernus Pharmaceuticals, Inc. on July 2, 2013, covering events occurring on June 26 and June 27, 2013. The filing addresses a specific intellectual property event regarding the company's product Oxtellar XR.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
On June 26, 2013, Supernus received a Paragraph IV Notice Letter from Watson Laboratories, Inc. This notice advised Supernus that Watson had filed an Abbreviated New Drug Application (ANDA) seeking FDA approval for generic oxcarbazepine extended-release tablets. This represents a potential challenge to the exclusivity of Supernus's Oxtellar XR product.
Outlook, Risks, and Management Commentary
- Management Response: Supernus is reviewing the details of the Notice Letter and intends to vigorously enforce its intellectual property rights.
- Patent Status: Oxtellar XR is currently protected by two issued patents listed in the FDA's Orange Book.
- Risks: The filing of the ANDA by Watson introduces the risk of generic competition if the patent challenges are successful or if the FDA grants approval despite the patent listing.
Investor Verification Checklist
- Verify the specific patent numbers and expiration dates for the two issued patents protecting Oxtellar XR.
- Monitor the status of the Paragraph IV litigation and any subsequent court filings or FDA responses.
- Review the attached press release (Exhibit 99.1) for additional details on the Notice Letter.
- Assess the potential impact of generic entry on Oxtellar XR's projected revenue stream.